“…Although considered safe, even in high dose, IVIG can cause thromboembolic events such as stroke, myocardial infarctus, deep vein thrombosis and/or pulmonary thrombosis, peripheral arterial occlusion, spinal arterial occlusion and retinal infarct, superficial vein thrombosis, central retinal vein thrombosis and transvers sinus vein thrombosis (2-6). To date, as far as we know, there are 5 cases in the literature that CRVO is developed with IVIG treatment and none of these cases have dermatological disease (2)(3)(4)(5)(6). Table 1 shows the summary of these cases.…”